Details for Patent: 8,629,171
✉ Email this page to a colleague
Which drugs does patent 8,629,171 protect, and when does it expire?
Patent 8,629,171 protects DAKLINZA and is included in one NDA.
This patent has twenty-five patent family members in twenty countries.
Summary for Patent: 8,629,171
| Title: | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methy- lbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-me- thylpropyl)carbamate dihydrochloride salt |
| Abstract: | The present disclosure generally relates to a crystalline form of methyl ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-met- hylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2- -yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt. The present disclosure also generally relates to a pharmaceutical composition comprising a crystalline form, as well of methods of using a crystalline form in the treatment of Hepatitis C and methods for obtaining such crystalline form. |
| Inventor(s): | Kim; Soojin (Demarest, NJ), Gao; Qi (Wallingford, CT), Yang; Fukang (Madison, CT) |
| Assignee: | Bristol-Myers Squibb Company (Princeton, NJ) |
| Application Number: | 12/175,104 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Use; |
Drugs Protected by US Patent 8,629,171
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol-myers Squibb | DAKLINZA | daclatasvir dihydrochloride | TABLET;ORAL | 206843-001 | Jul 24, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | METHOD OF INHIBITING HEPATITIS C VIRUS | ⤷ Sign Up | ||
| Bristol-myers Squibb | DAKLINZA | daclatasvir dihydrochloride | TABLET;ORAL | 206843-002 | Jul 24, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | METHOD OF INHIBITING HEPATITIS C VIRUS | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,629,171
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 070016 | ⤷ Sign Up | |||
| Argentina | 104566 | ⤷ Sign Up | |||
| Australia | 2008284100 | ⤷ Sign Up | |||
| Brazil | PI0815142 | ⤷ Sign Up | |||
| Canada | 2695729 | ⤷ Sign Up | |||
| Chile | 2008002354 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
